Abstracts tagged "risk assessment"

Abstract Number: 1187 • ACR Convergence 2020
Red Cell Distribution Width Is Associated with ASCVD Risk Score and CVD in RA After Initiation of Methotrexate
Ibtissam Gad¹, Sofi Damjanovska², Lenche Kostadinova³, Alyssa Lange⁴, Christopher Burant⁴, Brigid Wilson⁵, Taissa Bej⁵, Nora Singer⁶, Maya Mattar⁷, David Zidar⁸ and Donald Anthony⁹, ¹Case Western Reserve/ Cleveland VA Medical Center, Cleveland Heights, OH, ²Case Western Reserve University/Cleveland VA Medical Center, Cleveland Heights, OH, ³(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Highland Heights, OH, ⁴Case Western Reserve University, Cleveland, ⁵Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, ⁶The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, ⁷Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, ⁸Case Western Reserve University/Cleveland VA Medical Center, Cleveland, ⁹Case Western Reserve University/Cleveland VA Medical Center/MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Rheumatoid arthritis (RA) has been shown to be associated with increased risk of cardiovascular disease (CVD) and mortality. Red cell distribution width (RDW) represents…
Abstract Number: 1193 • ACR Convergence 2020
Unsupervised Molecular Profile Clustering in the Serum of Rheumatoid Arthritis Patients Identifies Groups with Differential CV-risk SCORE: Modulation by Biological Therapies
Maria Luque-Tevar¹, Carlos Pérez-Sánchez¹, Pilar Font², Alejandra Maria Patiño-Trives¹, Montserrat Romero-Gomez², Desirée Ruiz-Vilchez², Sara Remuzgo-Martínez³, Raquel López-Mejías⁴, Iván Arias de la Rosa¹, Carmen Torres-Granados¹, María-Carmen Abalos-Aguilera¹, Rafaela Ortega-Castro², Alejandro Escudero-Contreras², Carlos Rodriguez-Escalera⁵, Jose Perez-Venegas⁶, Mª Dolores Ruiz-Montesinos⁶, Carmen Dominguez⁶, Carmen Romero-Barco⁷, Antonio Fernandez-Nebro⁸, Natalia Mena-Vazquez⁹, Jose Luis Marenco¹⁰, Julia Uceda-Montañez¹⁰, Mª Dolores Toledo-Coello¹¹, Nuria Barbarroja¹, M Angeles Aguirre², Eduardo Collantes², Miguel A Gonzalez-Gay¹² and Chary Lopez-Pedrera¹, ¹Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ³Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁵Hospital Universitario de Jaen, Jaén, Spain, ⁶Hospital Universitario Virgen Macarena, Sevilla, Sevilla, Spain, ⁷Hospital Clínico Universitario, Málaga, Málaga, Spain, ⁸University of Malaga, Malaga, Spain, ⁹Hospital Regional Universitario de Málaga, Málaga, Spain, ¹⁰Hospital Universitario Virgen de Valme, Sevilla, Sevilla, Spain, ¹¹Hospital Universitario de Jerez de la Frontera, Cádiz, Spain, Cádiz, Spain, ¹²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander
Background/Purpose: To identify specific molecular profiles associated to the enhanced cardiovascular (CV)-risk present in Rheumatoid Arthritis (RA) patients and their modulation by biologic disease modifying…
Abstract Number: 1286 • ACR Convergence 2020
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus by Physician Global Assessment of Disease Activity
May Choi¹, Emma Stevens², Hongshu Guan², Daniel Li³, Jack Ellrodt⁴, Benjamin Kargere⁴, Tianrun Cai², Kazuki Yoshida⁵, Brendan Everett² and Karen Costenbader⁶, ¹Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital, Boston, MA, ³Harvard, Columbus, OH, ⁴Williams College, Williamstown, ⁵Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The risk of cardiovascular disease (CVD), including myocardial infarction and stroke, is higher in SLE than in the general population. The excess risk of…
Abstract Number: 1328 • ACR Convergence 2020
Cardiac Biomarkers Are Associated with the Development of Cardiovascular Events in Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Ker-Ai Lee², Shadi Akhtari³, Raz Winer⁴, Paul Welsh⁵, Naveed Sattar⁵, Iain McInnes⁶, Vinod Chandran⁷, Paula Harvey⁸, Richard Cook², Dafna Gladman⁷, Vincent Piguet⁸ and Lihi Eder⁹, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Women's College Hospital, University of Toronto, North York, ON, Canada, ⁴Rambam Health Care Campus, Haifa, Israel, ⁵University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁸Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: N-terminal pro-brain-type natriuretic peptide (NT-proBNP) and troponin I (TnI) are established cardiac biomarkers that predict cardiovascular events (CVEs) and mortality in apparently healthy individuals…
Abstract Number: 1475 • ACR Convergence 2020
Predictors of Thirty-Day Hospital Readmissions in Systemic Lupus Erythematosus in the US: A Nationwide Study
Rayan Najjar¹, Swetha Ann Alexander², Grant Hughes¹, Jinoos Yazdany³ and Namrata Singh⁴, ¹University of Washington, Seattle, WA, ²University of Connecticut, Hartford, CT, ³UCSF, San Francisco, CA, ⁴University of Washington, Bellevue, WA
Background/Purpose: For individuals with systemic lupus erythematosus (SLE), hospital readmission rate is associated with quality of care and prognosis. Our objective was to evaluate independent…
Abstract Number: 0181 • ACR Convergence 2020
Methotrexate Use Does Not Increase the Prevalence of Hepatic Steatosis: A Real-World Retrospective Nested Case-Control Study
Yunjung Choi¹, Chang-Hun Lee¹, Myeung-Su Lee², Chang-Hoon Lee², SoJeong Park³ and Wan-Hee Yoo⁴, ¹Jeonbuk National University Hospital, Jeonju, Republic of Korea, ²Wonkwang University Hospital, Iksan, Republic of Korea, ³Data Science Team, Hanmi Pharm. Co., Ltd, Seoul, Romania, ⁴Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea
Background/Purpose: We aimed to determine whether methotrexate (MTX) treatment in patients with rheumatoid arthritis (RA) leads to the development of nonalcoholic fatty liver (NAFL).Methods: Data…
Abstract Number: 1576 • ACR Convergence 2020
Acute Respiratory Viral Adverse Events During Use of Antirheumatic Disease Therapies: A Scoping Review
Adam Kilian¹, Yu Pei Eugenia Chock², Irvin Huang³, Elizabeth Graef⁴, Laura Upton⁵, Aneka Khilnani⁶, Sonia Silinsky Krupnikova⁷, Ibrahim Almaghlouth⁸, Laura Cappelli⁹, Ruth Fernandez-Ruiz¹⁰, Brittany Frankel³, Jourdan Frankovich¹¹, Carly Harrison¹², Bharat Kumar¹³, Kanika Monga¹⁴, Jorge Rosario Vega¹¹, Namrata Singh¹⁵, Jeffrey Sparks¹⁶, Elaine Sullo⁶, Kristen Young¹⁷, Ali Duarte-Garcia¹⁸, Michael Putman¹⁹, Sindhu Johnson²⁰, Jean Liew³ and Aruni Jayatilleke²¹, ¹George Washington University, Washington, DC, ²Yale School of Medicine, Greenwich, CT, ³University of Washington, Seattle, WA, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Georgetown University School of Medicine, Washington, DC, ⁶The George Washington University School of Medicine and Health Sciences, Washington, DC, ⁷The George Washington University School of Medicine and Health Sciences, Rockville, MD, ⁸King Saud University, Riyadh, Saudi Arabia, ⁹Johns Hopkins School of Medicine, Baltimore, MD, ¹⁰New York University School of Medicine, New York, ¹¹Temple University, Philadelphia, PA, ¹²Lupus Chat, NA, ¹³University of Iowa Hospitals and Clinics, Iowa City, IA, ¹⁴UT Health Rheumatology, HOUSTON, TX, ¹⁵University of Washington, Bellevue, WA, ¹⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁷University of Texas Southwestern Medical Center, Dallas, TX, ¹⁸Mayo Clinic, Rochester, MN, ¹⁹Northwestern University, Chicago, IL, ²⁰University of Toronto, Toronto, ON, Canada, ²¹Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
Background/Purpose: COVID-19 threatens the health of people worldwide, although it remains unclear to what extent antirheumatic disease therapies increase susceptibility to complications of viral respiratory…
Abstract Number: 0225 • ACR Convergence 2020
Prevalence and Probability Assessment of Adverse Drug Reactions in Rheumatoid Arthritis Patients Receiving Intravenous Originator Biologics in Saudi Arabia: A Longitudinal Five Years Follow-up Study
Hawazin Alhazzani¹, Reem Tashkandi¹, Lamia Alzamel¹, Haya Almalag¹, Shiekha Alaujan¹, Abdurhman Alarfaj¹, Hussain Alarfaj¹ and Mohammed Omair¹, ¹King Saud University, Riyadh, Saudi Arabia
Background/Purpose: Biologics have been advocated by guidelines as effective therapies for rheumatoid arthritis (RA)1. Limited longitudinal studies investigated the prevalence and risk factors for developing…
Abstract Number: 1579 • ACR Convergence 2020
Assessing the Effect of Calcineurin Inhibitors for Immune-related Adverse Event Management on Tumor Response
Pankti Reid¹, Daniel Olson² and Thomas Gajewski², ¹University of Chicago, Chicago, IL, ²University of Chicago Medical Center, Department of Medicine, Section of Hematology Oncology, Chicago
Background/Purpose: High grade immune-related adverse events (irAEs) to cancer immune checkpoint inhibitors (ICI) require considerable immunosuppression (IS) with high-dose steroids and steroid-sparing IS (SSIS) for…
Abstract Number: 045 • 2020 Pediatric Rheumatology Symposium
No-Shows: a Search for Modifiable Risk Factors
Samantha Ong ¹, Xujia Li ¹ and Austin Dalrymple², ¹Saint Louis University School of Medicine, St. Louis, ²Saint Louis University School of Medicine, Saint Louis, Missouri
Background/Purpose: Missed ambulatory visits, or “no-shows,” limit patient access, increase costs, occupy provider time, and lead to worse patient outcomes. Only a few studies have…
Abstract Number: 1758 • 2019 ACR/ARP Annual Meeting
Development of Ultrasound Detectable Arthritis Among ACPA Positive Subjects with Musculoskeletal Symptoms: The Risk RA Prospective Study
Aase Hensvold¹, Yogan Kisten ², Alexandra Circiumaru ¹, Monika Hansson ³, Meng Sun ¹, Guozhong Fei ⁴, Nancy Vivar ², Erik af Klint ², Hamed Rezaei ², Lars Klareskog ³, Aleksandra Antovic ⁵ and Anca Catrina ³, ¹Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, ²Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁴Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Sweden, ⁵Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Studies have shown that anti-citrullinated protein antibodies (ACPA) are a risk factor for the development of arthritis. We aimed to investigate in a prospective…
Abstract Number: 1960 • 2019 ACR/ARP Annual Meeting
Pleiotropy of Genetic Predisposition to Rheumatoid Arthritis Increases the Risk for Autoimmune Disease
Vivian Kawai¹, Mingjian Shi ¹, Qiping Feng ², Cecilia Chung ¹, Ge Liu ², Nancy Cox ², Dan Roden ², C. Michael Stein ¹ and Jonathan Mosley ², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder that is associated with increased risk of cardiovascular disease, cardiometabolic disorders, and autoimmune disease. Thus, we…
Abstract Number: 2136 • 2019 ACR/ARP Annual Meeting
Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)” Study Group of the Italian Society of Rheumatology
Fabio Cacciapaglia¹, Gian Luca Erre ², Garifallia Sakellariou ³, Ombretta Viapiana ⁴, Matteo Piga ⁵, Elena Bartoloni ⁶, Andreina Manfredi ⁷, Sergio Colella ¹, Floriana Castagna ², Giacomo Cafaro ⁸, Martina Dessì ⁵, Marco Fornaro ¹, Alessandro Giollo ⁹, Silvia Grignaschi ¹⁰, Caterina Vacchi ¹¹, Francesca Romana Spinelli ¹², Fabiola Atzeni ¹³ and Elisa Gremese ¹⁴, ¹Rheumatology Unit – Department of Emergency and Organs Transplantation, University and AOU Policlinico of Bari, Italy, Bari, Italy, ²Specialità Mediche, Azienda Ospedaliero Universitaria di Sassari, Italy., Sassari, Italy, ³Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁴University of Verona, Verona, Italy, ⁵Rheumatology Unit, Department of Medical Sciences, University and AOU Policlinico of Cagliari, Italy., Cagliari, Italy, ⁶Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ⁷Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Emilia-Romagna, Italy, ⁸Rheumatology Unit, Department of Medicine, University of Perugia, Italy., Perugia, Italy, ⁹Rheumatology Unit, Department of Medicine, University of Verona, Italy., Verona, Italy, ¹⁰Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy., Pavia, Italy, ¹¹Rheumatology Unit, Department of Medical and Surgical Science, University and AOU Policlinico of Modena, Italy., Modena, ¹²Rheumatology, Department of Internal Medicine and Medical Speciality, Sapienza University of Rome, Italy., Rome, Italy, ¹³Rheumatology Unit, University of Messina, Messina, Italy., Messina, Italy, ¹⁴Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients present high cardiovascular (CV) morbidity and mortality. International guidelines suggest estimating CV-risk in these patients,…
Abstract Number: 2322 • 2019 ACR/ARP Annual Meeting
Toward Cardiovascular Risk Stratification in Rheumatoid Arthritis: Use of Regression Tree Analyses to Evaluate Impact of Serum Biomarkers and Cardiovascular Risk Factors on Carotid Intima Media Thickness
Kimberly Liang¹, Yaming Li ¹, Suresh Mulukutla ¹, Steven Reis ¹, Marc Levesque ¹, Donald Jones ¹, Rachel Gartland ¹, Jennifer Avolio ¹, Ali Hakim Shoushtari ¹, Flordeliza Villanueva ¹, Larry Moreland ¹ and Douglas Landsittel ², ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, RI
Background/Purpose: Both traditional cardiovascular (CV) risk factors and disease-related factors contribute to the increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). Mechanisms of…
Abstract Number: 2539 • 2019 ACR/ARP Annual Meeting
Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)
Sooyeon Kwon¹, Jessica Farrell ², Sarfaraz Hasni ³ and Shubhasree Banerjee ², ¹The Center For Rheumatology, Loudonville, NY, ²The Center for Rheumatology, LLC, Albany, NY, ³NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: Hydroxychloroquine (HCQ) is recommended in all patients with systemic lupus erythematosus (SLE). Studies suggest that a significant proportion of subjects are non-adherent to daily…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].